Sat, May
7 New Articles
  • Hookipa Biotech Announces Nature Communications Publication Showing TheraT® Turns Cold Tumors Hot

    May 26, 2017 | 09:00 am

    B3C newswire (http://www.b3cnewswire.com/home.html) -- Hookipa Biotech AG (http://hookipabiotech.com/), a company pioneering a new class of immunotherapies for oncology and infectious diseases, today announces publication in leading peer-reviewed publication Nature Communications(1) of research data in a transgenic mouse model showing how its replicating viral vector platform TheraT® delivers potent innate immune activation including

  • ChromaDex Announces Closing of Second Tranche of the $25 Million Strategic Investment Led by Mr. Li Ka-shing

    May 25, 2017 | 20:05 pm

    IRVINE, Calif., May25, 2017(GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today the closing of the $16.4 million second tranche of the strategic investment of up to $25 million led by Hong Kong business leader[…]

  • Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

    May 25, 2017 | 12:05 pm

    Abeona’s Third Gene Therapy Program to Receive FDA Orphan DesignationEB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in Ongoing Phase 1/2 Clinical Trial NEW YORK and CLEVELAND, May25, 2017(GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that[…]

  • BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial

    May 25, 2017 | 12:00 pm

    RESEARCH TRIANGLE PARK, N.C., May25, 2017(GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced results from a second interim analysis of its Phase 2 APeX-1 clinical trial in hereditary angioedema (HAE). APeX-1 is a 3-part dose ranging trial designed to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered once-daily (QD) BCX7353 for 28 days, as a preventative[…]

  • New High Performance Filtration Plates from Biotage

    May 23, 2017 | 11:15 am

    Uppsala, Sweden, May 23, 2017 B3C newswire -- Biotage (http://www.biotage.com) (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, is pleased to announce the launch of ISOLUTE® FILTER+ high performance filtration plates (http://www.biotage.com/product-page/isolute-filter-high-performance-filtration-plates), for the processing of samples prior to UPLC-MS/MS, alongside a diverse range of other filtration applications.ISOLUTE® FILTER+ plates offer high[…]

  • Summit Announces Key Appointments to Strengthen Research and Development Team

    May 23, 2017 | 11:00 am

    Dr David Roblin to combine Chief Operating Officer and Chief Medical Officer roles Dr Anne Heatherington appointed Head of Clinical Development and Quantitative SciencesDr Dave Powell appointed Head of ResearchOXFORD, United Kingdom, May23, 2017(GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection (‘CDI’), today[…]

  • Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD

    May 22, 2017 | 20:05 pm

    NEW YORK, May22, 2017(GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, presented a poster on May 20, 2017, entitled “Phase 2 Multisite Double-Blind Placebo-Controlled Trial of TNX-102 SL in Military-Related Posttraumatic Stress Disorder: Mediators and Moderators of Treatment Response” (Poster No. 3001130) at the 72nd Annual[…]

  • Norwegian Study Confirms the Potential Health Benefits of Pressure Based Compression in Accordance with Sigmascreening’s Sensitive Paddle Concept for Mammography Equipment

    May 22, 2017 | 13:30 pm

    Fewer false positives, fewer false negatives and reduced unnecessary painNorwegian study(1) on 261,000 mammograms clearly proves Sigma’s hypothesis that pressure has a clear relation with the most optimal results in mammography like cancer detectionSensitive Sigma Paddle; the first pressure based compression paddle for mammography equipment taking into account breast size and tissue stiffness, generating reproducible mammograms for improved cancer detection,[…]

  • EDAP Announces CMS Approval of New Reimbursement Code for HIFU Ablation of the Prostate

    May 22, 2017 | 13:00 pm

    Billing code will take effect July 1st, 2017LYON, France, May22, 2017(GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that the Centers for Medicare and Medicaid Services (CMS) have established a new billing code for HIFU ablation of prostate tissue.A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a94c40ad-b3a4-4d46-a5e7-a73a4873fcf9"We are elated by CMS's decision," said[…]

  • Arbutus Presents HBV Drug Combination Studies at ICAR

    May 22, 2017 | 11:00 am

    Combinations of Arbutus’ RNAi or Capsid Assets with Approved Drugs Demonstrate Complementary ActivityDr. Michael J. Sofia, Arbutus’ Chief Scientific Officer, Awarded International Society of Antiviral Research Gertrude Elion AwardVANCOUVER, British Columbia and WARMINSTER, Pa., May22, 2017(GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today presented results from preclinical studies of HBV drugs[…]

  • Crown Bioscience Announces Record Breaking Growth With First 2017 Quarter Results

    May 19, 2017 | 11:56 am

    SANTA CLARA, Calif., May19, 2017(GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, announces continued growth in 2017 with dramatic first quarter results.In Q1 17 revenue reached NT$493 million, a 34% YOY (year-over-year) growth. Gross margin reached[…]

  • Kraig Biocraft Laboratories Delivers First Dragon Silk Fiber Samples to US Army

    May 19, 2017 | 10:05 am

    ANN ARBOR, Mich., May19, 2017(GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that it has delivered the first samples of Dragon Silk to the US Army for independent testing.  The Company provided several samples of individual silk filaments as well as finished Dragon Silk thread for evaluation."We are pleased[…]

  • Emperra Wins the 2017 Game Changers Award for Digital Business Models

    May 19, 2017 | 07:00 am

    Emperra GmbH (http://www.emperra.com), a start-up company based in Potsdam, Germany, has received the Finance Monthly’s 2017 Game Changers Award. The award is honouring Emperra for its new digital business models, which based on innovative hardware enable business revenue to be generated from digital solutions. The 2017 Game Changers Awards honour the innovation and strategic vision of a number of globally[…]

  • New Mass Detector for Flash Chromatography from Biotage

    May 18, 2017 | 16:30 pm

    Biotage (http://www.biotage.com/) (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, is pleased to announce the launch of Isolera™ Dalton 2000 (http://www.biotage.com/product-page/isolera-dalton-2000), a new mass detector for flash purification that expands functionality through a wider detection range of ion masses, up to m/z 2000, and new analysis features.Isolera™ Dalton 2000 is seamlessly integrated[…]

  • Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues at World Advanced Therapies and Regenerative Medicine Congress

    May 18, 2017 | 12:05 pm

    SAN DIEGO, May18, 2017(GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today presented new preclinical data showing extended survival and sustained functionality of its 3D bioprinted human liver tissue when implanted into diseased animal models. This data was presented at the World Advanced Therapies and[…]

  • Myriad Genetics to Present Seven Studies at the 2017 American Society of Clinical Oncology Annual Meeting

    May 18, 2017 | 11:05 am

    SALT LAKE CITY, May18, 2017(GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from seven studies at the 2017 American Society of Clinical Oncology (ASCO) annual meeting to be held June 2 to 6, 2016 in Chicago, Ill.  Abstracts of the Company's presentations are currently available at: abstracts.asco.org“We[…]

  • Data from Clinical Study of NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress

    May 18, 2017 | 10:00 am

    AMES, Iowa, May18, 2017(GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that an abstract describing data from a clinical study of its IDO pathway inhibitor, indoximod, in combination with chemotherapeutic agents for patients with newly diagnosed acute myelogenous leukemia (AML), is now available on the website of the European Hematology Association (EHA) Annual Congress.An infographic accompanying this announcement is[…]

  • Amarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular Care

    May 18, 2017 | 10:00 am

    BEDMINSTER, N.J. and DUBLIN, Ireland, May18, 2017(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today three new studies it is coordinating with leading health organizations and physicians. These studies are described in abstracts presented this week at the National Lipid Association (NLA) 2017 Scientific Sessions in Philadelphia.Two[…]

  • Xeris Pharmaceuticals Announces Closing of $30 Million Financing

    May 17, 2017 | 23:00 pm

    CHICAGO, IL and AUSTIN, TX, May17, 2017(GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on the development and commercialization of novel formulations of ready-to-use injectable drugs, today announced the closing of a $30 million financing.  The Series C financing was led by Redmile Group.  Other participants in the financing included current investors such as Deerfield Management Company,[…]

  • Data from Clinical Studies of NewLink Genetics’ Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017

    May 17, 2017 | 21:05 pm

    AMES, Iowa, May17, 2017(GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two clinical studies of its IDO pathway inhibitors, indoximod and navoximod (GDC-0919), used in combination with other agents, are now available on the website of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.An infographic accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b945495b-6286-4184-881f-b4ea49aa46b4“The IDO pathway is[…]

  • Sartorius Stedim Biotech Partners with Nova Biomedical

    May 17, 2017 | 09:00 am

    Sartorius Stedim Biotech (https://www.sartorius.com) (SSB), a leading international supplier to the biopharmaceutical industry, today announced an agreement with Nova Biomedical (http://www.novabiomedical.com) (Nova), a well-known US manufacturer of cell culture analyzers, to integrate their BioProfile® FLEX2 into the ambr® multi-parallel bioreactor systems for automated, at-line cell culture analytics.SSB and Nova are

  • Beactica Announces Glioblastoma Research Collaboration with Uppsala University and the DDD Platform at SciLifeLab

    May 16, 2017 | 12:00 pm

    Beactica AB (http://www.beactica.com/), the Swedish drug discovery company, today announced a new research collaboration with Uppsala University and the Drug Discovery and Development Platform at SciLifeLab to study the effects on brain cancer stem cells of specific small molecules under development by Beactica.The goal of the collaboration is to evaluate and characterize the pre-clinical efficacy of Beactica’s allosteric modulators of[…]

  • CellGenix Appoints Leading Experts to Scientific Advisory Board

    May 15, 2017 | 14:00 pm

    CellGenix (http://www.cellgenix.com/), a global leader in providing GMP-grade raw materials for cell and gene therapy and tissue-engineered products, today announced the appointment of highly experienced and internationally respected experts in the field of cell and gene therapy to its Scientific Advisory Board (SAB). The SAB will serve as a strategic resource to CellGenix as it continues to develop high quality[…]

  • BioNTech Announces Positive Results of an International Reproducibility Study with MammaTyper®

    May 15, 2017 | 09:40 am

    International multicenter study in ten pathology laboratories in the U.S., Canada, Europe and AsiaMammaTyper® provides highly reproducible quantitative results of the mRNA expression status of the four biomarkers HER2 (ERBB2), ER (ESR1), PR (PGR) and Ki-67 (MKI67)Mainz, Germany, May 15, 2017 B3C newswire -- BioNTech Diagnostics GmbH today announced the publication of an international prospective multicenter study that demonstrates the[…]

  • Isarna Presents Positive Clinical Data for ISTH0036 in Advanced Glaucoma and Preclinical Data Supportive of AMD/DME Potential at ARVO 2017 Annual Conference

    May 15, 2017 | 09:00 am

    B3C newswire (http://www.b3cnewswire.com/home.html) -- Isarna Therapeutics (http://www.isarna-therapeutics.com/), the leader in transforming growth factor beta (TGF-β) isoform targeted antisense therapeutics, today announced the presentation of the Phase I safety and efficacy data for its lead candidate ISTH0036, a locked nucleic acid-modified antisense oligonucleotide, in advanced-stage glaucoma patients. Overall, the treatment was safe and well

  • NeuroDigm Uses Tissue Repair in an Innovative Nerve Pain Model

    May 12, 2017 | 07:00 am

    NeuroDigm (http://www.neurodigm.com/), dedicated to translating clinical knowledge into a new platform for research and development focused on neural pain, today announced that Mary Hannaman MD, president, will speak at Seligman Medical Institute’s (SMI) 17th annual Pain Therapeutics Conference May 22 – 23, 2017 in London, UK.Neuropathic pain, a common form of disabling chronic pain, has long been considered “incurable”, and[…]

  • BioPharmaSpec Announces Expansion of In-house Analytical Capabilities

    May 9, 2017 | 12:00 pm

    BioPharmaSpec (http://biopharmaspec.com/), a leading contract research organization (CRO) providing a full range of characterization services for the biotechnology industry, today announced it is expanding the range of its in-house capabilities for characterizing higher order protein structure. The new in-house services allow Clients access to an increased range of BioPharmaSpec’s flexible, expert characterization methods to accurately

  • Sartorius Stedim Biotech Launches Chemistry Testing Services

    May 4, 2017 | 12:30 pm

    Goettingen, Germany, Glasgow, UK, May 04, 2017 B3C newswire -- Sartorius Stedim Biotech (http://www.sartorius-stedim.com/) (SSB), a leading international supplier for the biopharmaceutical industry, announced the launch of a full range of chemistry testing services. Offered by its subsidiary BioOutsource (http://www.biooutsource.com), they characterize the physicochemical properties and structural attributes of therapeutic monoclonal antibodies (mAbs). The service platform methods have been developed[…]

  • AlzProtect : The American Food and Drug Administration (FDA) Has Granted AZP2006 the Orphan Drug Designation for the Treatment of Progressive Supranuclear Palsy (PSP)

    May 4, 2017 | 08:30 am

    AlzProtect (http://www.alzprotect.com/en/), a biopharmaceutical company committed to the development of drugs for the treatment of neurodegenerative diseases, today announces the decision of the US FDA to grant orphan drug status to AZP2006 (http://www.alzprotect.com/en/rd/azp2006-clinical-trials/) for the treatment of Progressive Supranuclear Palsy (PSP).This orphan drug

  • Hookipa Biotech Presents Positive Data from Phase 1 First-In-Human Trial of Vaccine Against Cytomegalovirus

    May 4, 2017 | 08:00 am

    Hookipa Biotech AG (http://hookipabiotech.com/), a company pioneering a new class of immunotherapies for oncology and infectious diseases, today presented the un-blinded safety and immunogenicity data through month four from the Company’s phase 1 first-in-human trial of